Skip to main content

Table 1 Patients’ characteristics

From: Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer

Background n (%)
Age
  < 70 years 275 (74)
  ≥ 70 years 99 (26)
Gender
 Male 322 (86)
 Female 52 (14)
ECOG performance status
 0 234 (63)
 1 121 (32)
 2 16 (4)
 3 3 (1)
Body mass index
  < 20 97 (26)
  ≥ 20 277 (74)
Primary site
 Larynx 57 (15)
 Nasopharynx 48 (13)
 Hypopharynx 132 (34)
 Nasal sinus 21 (6)
 Oropharynx 101 (27)
 Oral cavity 14 (4)
 Ear canal 1 (1)
T-classification
 1 32 (9)
 2 136 (36)
 3 86 (23)
 4a 92 (25)
 4b 28 (7)
N-classification
 0 76 (20)
 1 54 (15)
 2a 19 (5)
 2b 134 (36)
 2c 75 (20)
 3 16 (4)
Tumor histology
 SCC 347 (93)
 Others 27 (7)
Brinkman index
  < 500 131 (35)
  ≥ 500 243 (65)
Habitual alcoholic consumption
 Yes 221 (59)
 No 153 (41)
Use of ACEi or ARB
 Yes 69 (18)
 No 305 (82)
Use of PPI or H2 blocker
 Yes 198 (53)
 No 176 (47)
Oral hygiene before treatment
 Good 179 (48)
 Poor 183 (52)
Coexistence of other malignancies
 Yes 45 (12)
 No 329 (88)
Charlson comorbidity index
 0–1 293 (78)
  ≥ 2 81 (22)
Serum albumin before treatment
 Within normal limits 313 (84)
 Less than normal range 61 (16)
Hemoglobin before treatment
 Within normal limits 265 (71)
 Less than normal range 109 (29)
Use of sleeping pills before treatment?
 Yes 185 (49)
 No 189 (51)
Induction chemotherapy
 Yes 97 (26)
 No 277 (74)
Concurrent chemotherapy regimen
 CDDP-based 278 (74)
 CBDCA-based 64 (17)
 Cetuximab 32 (9)
Radiation technique
 Conventional 3D-CRT 253 (68)
 IMRT 121 (32)
Radiation dose, Gy
 70Gy 363 (97)
 60-70Gy 3 (1)
  < 60Gy 8 (2)
Irradiation field
 Local 67 (18)
 Whole neck 307 (82)
Percutaneous endoscopic gastrostomy prior to treatment
 Yes 229 (61)
 No 155 (39)
Treatment
 Inpatient 185 (49)
 Outpatient 189 (51)